Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508).
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, reviews data from a retrospective analysis that compared the real-world effectiveness of monotherapy first-line treatment for patients with chronic lymphocytic leukemia (CLL) based on overall survival and time to next treatment (Abstract 7045).
Manali Kamdar, MD, of the University of Colorado, discusses a rapid oral abstract session that highlighted three trends in the field of lymphomas: improving outcomes in frontline diffuse large B-cell lymphoma, continued development of cellular therapies, and expanding molecular profiling.
Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).
Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluating ivonescimab in combination with FOLFOX as front-line therapy in locally advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma (Abstract TPS4246).
Yashasvini Sampathkumar, MD, of Memorial Sloan Kettering Cancer Center, presents data on Talking to Employers and Medical Staff about Work (TEAMWork), an English/Spanish intervention. The English/Spanish intervention, delivered as a booklet or mobile app, was developed to improve work outcomes among women undergoing breast cancer therapy. Dr. Sampathkumar discusses whether the digital vs print format was preferable among this population (Abstract 11060).
